Incidence of breast cancer in patients aged < 20 years has been estimated to be 0.1 per 100,000 women. Reported incidences are 1.4 for women aged 20-24 years, 8.1 for women aged 25-29 years, and 24.8 for women aged 30-34 years. Younger patients have been found to have a more aggressive presentation of disease at diagnosis, which is associated with dire prognoses compared with those in premenopausal older patients. Several biologic features might explain the more aggressive behavior of breast cancer in younger patients: higher grade and higher expression of Ki67, higher occurrence of vessel invasion, and less expression of estrogen and progesterone receptors. Choice of adjuvant therapies for women aged < 35 years with breast cancer is based on data derived from trials on cohorts of older patients. On average, the effect of chemotherapy for premenopausal patients is substantial: recent evidence suggested that very young women with endocrine-responsive tumors had a higher risk of relapse than older premenopausal patients with similar tumors. This was not the case for patients with endocrine-nonresponsive tumors, for which effects of chemotherapy were similar across ages. Very young women with this disease are faced with personal, family, professional, and quality-of-life issues that further complicate the phase of treatment decision-making. The development of more effective therapies for very young women with breast cancer requires tailored treatment investigations and research focused on issues specific to these patients.

Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features / G. Curigliano, R. Rigo, M. Colleoni, F.G.M. DE BRAUD, F. Nolè, V. Formica, L. Orlando, S. Cinieri, R. Torrisi, A. Cardillo, G. Peruzzotti, M. Medici, R. Ardito, I. Minchella, A. Goldhirsch. - In: CLINICAL BREAST CANCER. - ISSN 1526-8209. - 5:2(2004 Jun), pp. 125-130. [10.3816/CBC.2004.n.016]

Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features

G. Curigliano;F.G.M. DE BRAUD;
2004

Abstract

Incidence of breast cancer in patients aged < 20 years has been estimated to be 0.1 per 100,000 women. Reported incidences are 1.4 for women aged 20-24 years, 8.1 for women aged 25-29 years, and 24.8 for women aged 30-34 years. Younger patients have been found to have a more aggressive presentation of disease at diagnosis, which is associated with dire prognoses compared with those in premenopausal older patients. Several biologic features might explain the more aggressive behavior of breast cancer in younger patients: higher grade and higher expression of Ki67, higher occurrence of vessel invasion, and less expression of estrogen and progesterone receptors. Choice of adjuvant therapies for women aged < 35 years with breast cancer is based on data derived from trials on cohorts of older patients. On average, the effect of chemotherapy for premenopausal patients is substantial: recent evidence suggested that very young women with endocrine-responsive tumors had a higher risk of relapse than older premenopausal patients with similar tumors. This was not the case for patients with endocrine-nonresponsive tumors, for which effects of chemotherapy were similar across ages. Very young women with this disease are faced with personal, family, professional, and quality-of-life issues that further complicate the phase of treatment decision-making. The development of more effective therapies for very young women with breast cancer requires tailored treatment investigations and research focused on issues specific to these patients.
Amenorrhea; Chemotherapy; Endocrine therapy; Estrogen receptor; Premenopausal patients; Progesterone receptor; Oncology; Cancer Research
Settore MED/06 - Oncologia Medica
giu-2004
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1526820911703585-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 128.26 kB
Formato Adobe PDF
128.26 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/656404
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 23
  • ???jsp.display-item.citation.isi??? ND
social impact